Neurones (FR:NRO)
:NRO
Top Page
Neurones
(NRO)
Select Model
Select Model
Rating:72Outperform
Price Target:
€43.00
▲(2.38% Upside)
Action:ReiteratedDate:12/02/25
Neurones' strong financial performance is the most significant factor, contributing to a solid overall score. The technical analysis suggests caution due to overbought signals, while the valuation indicates a fair price with a reasonable dividend yield. The absence of earnings call and corporate events data did not impact the score.
Positive Factors
Low leverage and strong equity base
Neurones' very low leverage and strong equity funding reduce refinancing and solvency risks, enabling resilient operations and capital allocation. This balance sheet strength supports strategic investments, M&A optionality, and dividend sustainability over the medium term.
Negative Factors
Modest operating margin
An EBIT margin below many software peers constrains internally available profits for reinvestment and cushions during downturns. Sustained mid-single-digit operating margins limit cash available for growth initiatives and reduce margin expansion potential over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and strong equity base
Neurones' very low leverage and strong equity funding reduce refinancing and solvency risks, enabling resilient operations and capital allocation. This balance sheet strength supports strategic investments, M&A optionality, and dividend sustainability over the medium term.
Read all positive factors
Neurones (NRO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€834.47M
Dividend Yield3.07%
Average Volume (3M)6.80K
Price to Earnings (P/E)20.1
Beta (1Y)0.42
Revenue Growth7.39%
EPS Growth4.58%
CountryFR
Employees6,849
SectorGeneral
Sector StrengthN/A
IndustryInformation Technology Services
Share Statistics
EPS (TTM)1.44
Shares Outstanding24,328,716
10 Day Avg. Volume4,639
30 Day Avg. Volume6,801
Financial Highlights & Ratios
PEG Ratio2.95
Price to Book (P/B)2.82
Price to Sales (P/S)1.32
P/FCF Ratio14.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.35
Revenue Forecast (FY)€904.35M
Neurones Business Overview & Revenue Model
Company Description
Neurones S.A., an information technology (IT) services company, provides infrastructure, application, and consulting services in France and internationally. Its infrastructure services include infrastructure management, clouds, user support, DevOp...
How the Company Makes Money
Neurones generates revenue through a multi-faceted model that includes project-based consulting services, subscription fees for software solutions, and maintenance contracts for IT infrastructure. Key revenue streams come from long-term contracts ...
Neurones Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 832.27M | 810.40M | 741.17M | 665.38M | 579.88M | 524.49M |
| Gross Profit | 619.18M | 388.76M | 346.76M | 81.64M | 69.73M | 68.61M |
| EBITDA | 82.28M | 85.92M | 96.63M | 88.72M | 76.23M | 68.78M |
| Net Income | 50.70M | 52.50M | 49.41M | 44.24M | 37.71M | 30.92M |
Balance Sheet | ||||||
| Total Assets | 717.70M | 725.69M | 674.25M | 616.22M | 567.82M | 549.85M |
| Cash, Cash Equivalents and Short-Term Investments | 288.70M | 326.49M | 297.76M | 272.06M | 265.17M | 266.60M |
| Total Debt | 41.47M | 42.02M | 43.98M | 35.57M | 35.32M | 34.18M |
| Total Liabilities | 286.04M | 289.52M | 266.34M | 240.63M | 214.90M | 190.83M |
| Stockholders Equity | 371.19M | 378.10M | 354.39M | 330.58M | 311.56M | 322.63M |
Cash Flow | ||||||
| Free Cash Flow | 76.63M | 72.34M | 54.09M | 44.33M | 58.10M | 61.80M |
| Operating Cash Flow | 88.22M | 84.38M | 72.08M | 54.94M | 64.68M | 68.99M |
| Investing Cash Flow | -18.60M | -19.69M | -21.57M | -12.26M | -10.62M | -8.01M |
| Financing Cash Flow | -44.37M | -34.48M | -27.06M | -36.08M | -55.42M | -11.05M |
Neurones Technical Analysis
Negative
42.00
Price Trends
36.67
Negative
39.74
Negative
40.80
Negative
Market Momentum
-0.61
Negative
44.29
Neutral
55.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:NRO, the sentiment is Negative. The current price of 42 is above the 20-day moving average (MA) of 34.60, above the 50-day MA of 36.67, and above the 200-day MA of 40.80, indicating a bearish trend. The MACD of -0.61 indicates Negative momentum. The RSI at 44.29 is Neutral, neither overbought nor oversold. The STOCH value of 55.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:NRO.
Neurones Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €1.11B | 9.75 | 12.87% | 0.84% | 7.00% | 20.56% | |
72 Outperform | €834.47M | 20.10 | 14.08% | 3.07% | 7.39% | 4.58% | |
72 Outperform | €520.52M | 19.04 | 12.71% | 2.54% | 1.02% | 6.31% | |
67 Neutral | €2.28B | 10.15 | 14.39% | 3.03% | -4.12% | 43.37% | |
57 Neutral | €1.82B | 23.95 | 6.98% | 2.08% | -0.23% | -37.70% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
41 Neutral | €729.76M | -0.69 | 319.82% | ― | -14.60% | ― |
* General Sector Average
FR:NRO
Neurones
34.30
-13.54
-28.30%
FR:ATE
ALTEN SA
52.15
-40.42
-43.66%
FR:ATO
Atos SE
36.95
2.35
6.79%
FR:AUB
Aubay Société Anonyme
40.90
-7.33
-15.20%
FR:SOP
Sopra Steria
112.50
-65.75
-36.89%
FR:WAVE
Wavestone
44.75
-3.85
-7.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.